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Abstract 
Efforts to characterize the late effects of traumatic brain injury (TBI) have been in progress for some time. In recent 
years much of this activity has been directed towards reporting of chronic traumatic encephalopathy (CTE) in former 
contact sports athletes and others exposed to repetitive head impacts. However, the association between TBI and 
dementia risk has long been acknowledged outside of contact sports. Further, growing experience suggests a 
complex of neurodegenerative pathologies in those surviving TBI, which extends beyond CTE. Nevertheless, despite 
extensive research, we have scant knowledge of the mechanisms underlying TBI‑related neurodegeneration (TReND) 
and its link to dementia. In part, this is due to the limited number of human brain samples linked to robust demo‑
graphic and clinical information available for research. Here we detail a National Institutes for Neurological Disease 
and Stroke Center Without Walls project, the COllaborative Neuropathology NEtwork Characterizing ouTcomes of TBI 
(CONNECT‑TBI), designed to address current limitations in tissue and research access and to advance understanding 
of the neuropathologies of TReND. As an international, multidisciplinary collaboration CONNECT‑TBI brings together 
multiple experts across 13 institutions. In so doing, CONNECT‑TBI unites the existing, comprehensive clinical and 
neuropathological datasets of multiple established research brain archives in TBI, with survivals ranging minutes to 
many decades and spanning diverse injury exposures. These existing tissue specimens will be supplemented by pro‑
spective brain banking and contribute to a centralized route of access to human tissue for research for investigators. 
Importantly, each new case will be subject to consensus neuropathology review by the CONNECT‑TBI Expert Pathol‑
ogy Group. Herein we set out the CONNECT‑TBI program structure and aims and, by way of an illustrative case, the 
approach to consensus evaluation of new case donations.
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Introduction
There are ongoing efforts to characterize the late effects 
of traumatic brain injury (TBI) [18]. In recent years, 
attention has focused on participation in contact sports 
and risk of the specific neurodegenerative disease, 
chronic traumatic encephalopathy (CTE). However, stud-
ies have shown that CTE is not restricted solely to this 
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population, nor is the risk of late neurodegeneration after 
TBI exclusively CTE [2]. Increased risk of a wide range 
of neurodegenerative diseases, including Alzheimer’s 
disease (AD) and Parkinson’s disease, has long been rec-
ognized following exposure to TBI outside of a sporting 
context. Indeed, an estimated 3–10% of dementia in the 
community is thought to be influenced by prior expo-
sure to TBI [9, 14, 24]. Despite this we know remark-
ably little about the pathophysiology and pathologies of 
TBI-related neurodegeneration (TReND), within which 
CTE represents just one of several late consequences of 
TBI [25]. A major impediment to research progress in 
this field is the limited number of suitable human brain 
tissue specimens with linked clinical information avail-
able for research. The National Institute of Neurological 
Disorders and Stroke (NINDS)-supported, Center With-
out Walls, the COllaborative Neuropathology NEtwork 
Characterizing ouTcomes of TBI (CONNECT-TBI), is 
designed to address the need for robust, comprehensively 
characterized research tissue resources to support inves-
tigator-led studies in TBI.
Exposure to a  TBI is acknowledged as one of the 
strongest environmental risk factors for early cognitive 
decline and dementia [5, 14, 15, 21], with a clinical phe-
notype typically reported similar to AD [4, 21]. However, 
prior studies on the etiology of dementia associated with 
TBI used chart reviews or clinical interviews for demen-
tia ascertainment, which are recognized to have a low 
specificity [13]. No prior study of TBI-associated demen-
tia has used pathologic confirmation of the dementia 
subtype, which is recognized as the gold standard [3]. 
Furthermore, no prior studies have used modern neu-
rodiagnostic tools, such as neuroimaging or biomarker 
assays in serum or plasma, which are recognized to pro-
vide refinements over the clinical diagnosis alone [29]. 
Thus, although the link between TBI and dementia is 
acknowledged, little data exist on the precise phenotypic 
features and natural history of TBI-associated cognitive 
impairment and dementia.
Consensus neuropathological criteria for the iden-
tification of CTE neuropathologic change are derived 
from review of relatively few cases from a single 
archive. While experience suggests these criteria may 
be highly specific, they may not be sufficiently sensi-
tive [16]. Furthermore, the focus on CTE, arguably, 
has occurred at the expense of developing a broader 
understanding of wider neurodegenerative outcomes 
and neuropathologies arising in those with a history of 
TBI [6, 24, 30]. For example, while the identification of 
CTE neuropathologic change is based on the regional 
pattern and distribution of hyperphosphorylated tau 
(pTau), multiple other proteinopathies, among other 
types of brain lesions, are often observed coinciding 
with tau abnormalities in many of the cases character-
ized thus far [24], including β-amyloid pathologies [26], 
α-synuclein pathology [1] and TDP-43 proteinopathy 
[17]. Furthermore, components of these pathologic 
changes are not exclusive to those exposed to repetitive 
mild TBI and have been observed after exposure to just 
a single moderate or severe TBI [10, 11, 27, 28].
As TReND is increasingly recognized as a major 
health concern [14], there is a clear and pressing need 
to adequately characterize the spectrum, extent and 
neuroanatomic distribution of the pathologies emerg-
ing in those exposed to TBI and their relationship 
to wider pathologies of aging and neurodegenera-
tion. In so doing, robust operational criteria for late 
TBI-related neuropathologies will be defined, which 
will, in turn, be critical to the development of robust 
diagnostic, mechanistic and interventional studies. 
CONNECT-TBI comprises an international, multidis-
ciplinary team of over 30 experts across 13 institutions 
representing unparalleled experience and resources in 
the investigation of the clinical and neuropathological 
consequences of TBI. Through this multicenter col-
laboration, CONNECT-TBI unites the existing, com-
prehensive clinical and neuropathological datasets of 
nine established research brain archives in TBI, several 
of which are unique and internationally regarded. In 
so doing, CONNECT-TBI provides an unrivalled, net-
worked resource of human tissue available for research 
in TBI spanning diverse injury exposures and popula-
tions, with survivals ranging minutes to many decades. 
These existing tissue specimens will be supplemented 
by prospective brain banking across each site, many 
including research participants in ongoing, longitudi-
nal clinical research programs studying outcomes from 
TBI, including Transforming Research and Clinical 
Knowledge in TBI (TRACK-TBI), Late Effects of TBI 
(LETBI), and the  Concussion Assessment, Research 
and Education (CARE) Consortium.
Methods
CONNECT‑TBI definitions
For the purposes of this program the following defini-
tions are used for mild, moderate and severe TBI [22]. 
A mild TBI is defined as a Glasgow Coma Score (GCS) 
at presentation of 13–15, a loss of consciousness of less 
than thirty minutes, normal structural imaging and post-
traumatic amnesia of less than 24 h. A moderate TBI is 
defined as a GCS of 9–12, loss of consciousness of more 
than 30 min but less than 24 h, and post-traumatic amne-
sia of more than 24 h but less than 7 days. A severe TBI 
is defined as a GCS of 3–8, loss of consciousness of more 
than 24  h, and post-traumatic amnesia of more than 
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7 days. Acute TBI is defined as survival of 6 months or 
less following TBI and cTBI as greater than 6  months 
survival from TBI.
CONNECT‑TBI program structure
The CONNECT-TBI program was formed under 
the umbrella of the NINDS Centers Without Walls 
(CWOW). This program structure is designed to bring 
together expertise from multiple international institu-
tions. The CONNECT-TBI program represents a center 
without walls to further the field’s understanding of TBI-
related neurodegeneration and associated neurocognitive 
decline.
CONNECT-TBI represents  a multi-site, multidisci-
plinary, research team working  synergistically to collate 
a unified, central dataset of archive holdings of human 
tissues available for research on TBI across participat-
ing centers. In parallel, CONNECT-TBI will compre-
hensively characterize the neuropathological features 
associated with TReND and neurocognitive decline in 
individuals with a history of TBI and assess the contri-
bution of key patient variables (sex, age at time of injury, 
survival time from injury, co-morbid medical condi-
tions, etc.) and injury characteristics (injury severity 
and frequency) to these neuropathological and clinical 
outcomes. A critical feature of the program will be the 
broad sharing of clinical and neuropathological data and 
the development of a digital resource for distribution and 
sharing of fully characterized research tissue sections. 
The CONNECT-TBI program is a cooperative agreement 
with NINDS and is structured around multiple cores, 
namely an Administrative Core, Data Coordinating Core, 
and a Brain Banking Core (Fig. 1).
The Administrative Core coordinates the integration 
and management of activities within CONNECT-TBI 
by providing internal and external project oversight and 
reviewing progress  against CONNECT-TBI milestones. 
The Administrative Core coordinates tissue archiving and 
access procedures for external, researcher-led enquiries, 
including institutional review and material transfer. To 
this end, the goals of the CONNECT-TBI Administrative 
Core include:
1. Establish multidisciplinary project oversight and 
review via an Internal Governance Committee and 
External Advisory Board.
2. Establish network governance procedures, including 
those to facilitate broad and enduring institutional 
review and material transfer agreement procedures 
for the CONNECT-TBI archive.
3. Create the CONNECT-TBI website which will: facili-
tate communication on program achievements; act 
as the access point for enquiries and tissue applica-
tions from external researchers; and as a central and 
accessible repository for all CONNECT-TBI pro-
gram-generated protocols.
4. Coordinate management of data transfer from CON-
NECT-TBI to the Federal Interagency Traumatic 
Brain Injury Research (FITBIR) informatics system.
5. Oversight and guidance of CONNECT-TBI will be 
directed through an independent External Advisory 
Board and an Internal Governance Committee that 
Fig. 1 Schematic of CONNECT‑TBI program
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will review activities against CONNECT-TBI mile-
stones and objectives. The External Advisory Board 
comprises a multidisciplinary group of recognized 
research leaders in TBI with extensive experience 
in large scale, multi-center collaborative research in 
TBI, networked research tissue archiving in neuropa-
thology and, researcher-led studies in TBI.
Enrollment and consent procedures and policies of 
each brain bank have been reviewed and approved by 
their respective Institutional Review Boards (IRB) and 
appropriate oversight committees, with central IRB 
approval specific to CONNECT-TBI program activi-
ties obtained from the University of Pennsylvania. The 
Administrative Core will ensure each collaborating 
brain bank center maintains their IRB approval. Mate-
rial Transfer Agreements between the University of 
Pennsylvania and participating CONNECT-TBI institu-
tions will allow for tissue to be freely transferred to the 
CONNECT-TBI central archive for staining and storage 
of digital scans.
The Brain Bank Core is coordinated through the Uni-
versity of Pennsylvania and provides a central point of 
access to comprehensive research resources to support 
global studies in outcomes from all exposure types and 
severities of TBI. To achieve this, the Brain Bank Core 
collates a centralized database of the extensive existing 
tissue holdings and associated clinical datasets across 
all CONNECT-TBI participating centers. In parallel, 
CONNECT-TBI facilitates coordinated research brain 
banking activities under harmonized protocols for the 
assessment and interrogation of autopsy material from 
patients exposed to TBI. Tissue is obtained from the fol-
lowing institutions: University of Pennsylvania, Univer-
sity of Glasgow, Harvard University, Mount Sinai, New 
York University, University of Pittsburgh, University of 
Toronto, Uniformed Services University of the Health 
Sciences, and University of Washington. Tissue was 
acquired at routine diagnostic autopsy, and approval for 
its use was granted by the respective Institutional Review 
Boards. The CONNECT-TBI Brain Bank Core serves as 
the coordinating and archiving center for these activi-
ties and acts as the central histologic processing site to 
facilitate the multi-institutional neuropathologic study of 
postmortem central nervous system tissues from patients 
exposed to TBI, including consensus group activities 
(Fig.  2). Eligible cases for inclusion in the CONNECT-
TBI resource, are existing research archives or new case 
donations with history of TBI (acute or chronic) with or 
without history of neurodegenerative disease, patients 
with history of neurodegenerative disease but no known 
history of TBI and patients with no known history of TBI 
or neurodegenerative diseases as controls.
For new brain donations collected under CONNECT-
TBI, each participating center generates a standardized 
slide set  that comprises paraffin tissue sections from 
16 anatomical regions, including the minimum recom-
mended regions of the NINDS preliminary consensus 
protocol for the neuropathological evaluation of CTE 
(Table 1) [16].
To provide histological staining  consistency, ten 
unstained, 8  μm formalin-fixed paraffin tissue sections 
from these defined brain regions will be sent to the Uni-
versity of Pennsylvania for standardized staining  and 
whole slide digital imaging. Sections are stained with 
Hematoxylin and eosin (H&E) and immunostained for 
hyperphosphorylated tau (PHF-1; 1:1000, Peter Davies), 
β-amyloid (6F/3D; 1:75, Dako), phosphorylated TDP-43 
(1D3; 1:500, Millipore), and α-synuclein (KM51; 1:200, 
Leica). The stained sections are then digitally scanned, 
with the resulting images made available to members of 
the CONNECT-TBI Expert Consensus Group (ECG) to 
Fig. 2 Outline of workflow, highlighting case submission, remote 
digital microscopy and expert consensus group review with all sites 
examining the same scanned section
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assess and score pathologies in advance of quarterly diag-
nostic case review conference calls. The purpose of gen-
erating high quality whole-slide images in this Brain Bank 
Core is to allow for rapid sharing of histologic images 
to CONNECT-TBI investigators to support proposed 
Research Projects. This unique infrastructure will thus 
allow for all the efficiencies of local autopsy tissue pro-
curement with centralized histologic slide staining, imag-
ing and efficient sharing of neuropathology images.
The Expert Consensus Group will evaluate representa-
tive cases of moderate or severe TBI (n = 15); repetitive 
mild TBI (n = 15) or blast TBI (n = 15) and age-matched 
controls (n = 15). Thereafter a further randomly selected 
150 cases and 50 controls representative of broad expo-
sures and survivals in cTBI patients will be evaluated. For 
each case, up to 13 independent CONNECT-TBI expert 
neuropathologists rate brain pathologies based on rec-
ognized established or preliminary consensus criteria for 
the neuropathological assessment of neurodegenerative 
pathologies. Despite the recent focus on tau pathologies 
currently defining CTE, the pathologies encountered 
in cTBI patients often are mixed, particularly in aged 
patients, with multiple proteinopathies present in a sin-
gle case. Thus, the prevalence of comorbid pathologies 
will be assessed. Specifically, each case is assessed blind 
to patient demographics and clinical information for the 
presence of:
1. Alzheimer’s disease neuropathologic changes 
(ADNC) [8],
2. CTE neuropathologic change (CTE-NC) [16],
3. Aging-related tau astrogliopathy (ARTAG) [12],
4. α-synuclein pathology [19],
5. TDP-43 pathology [20],
6. Cerebral amyloid angiopathy (CAA),
7. Cerebrovascular disease (CVD) [23].
In addition, comparisons will be made with other neu-
rodegenerative disorders to determine potentially unique 
and shared features of TReND with wider neurodegener-
ative conditions and, most importantly, non-injured age-
matched controls, given the importance of age as a risk 
factor for neurodegeneration [7].
Following review, Expert Consensus Group members 
return their assessments to the Brain Bank Core for col-
lation. At this point, Expert Consensus Group members 
are provided anonymized clinical summaries. Agreement 
on consensus is based on the Royal College of Patholo-
gists guidance for a diagnostic External Quality Assess-
ment scheme, where above three-quarters  agreement is 
taken as consensus. If below three-quarters  agreement, 
the Expert Consensus Group, armed with the patient’s 
clinical history, reviews the pathology real-time during 
the consensus call using the digital scanned slide, dis-
cusses views on the pathology and agrees a consensus 
opinion, if possible. Where consensus cannot be achieved 
after this review, the discordant views are recorded.
The Data Coordinating Core is developing a central 
standardized digital neuropathological and clinical data 
archive, through harmonization and collation of exist-
ing neuropathological and clinical data holdings across 
the CONNECT-TBI network of nine leading research 
centers. The Data Coordinating Core integrates exist-
ing patient data resources in TBI, historically held at 
Table 1 CONNECT-TBI standardized sampling and staining protocol
H&E p‑tau β‑amyloid TDP‑43 α‑synuclein
1 Sup frontal gyrus X X
2 Mid frontal gyrus X X X X X
3 Ant cingulate gyrus with corpus callosum X X X
4 Temporal pole X X X
5 Sup and mid temporal gyri X X X
6 Inf parietal lobule X X X
7 Hypothalamus incl mammillary body X X
8 Hippocampus and entorhinal cortex X X X X X
9 Striate cortex X X X
10 Amygdala X X X X
11 Thalamus X X X
12 Basal ganglia with nucleus basalis of Meynert X X X
13 Cerebellar cortex and dentate X X X
14 Midbrain X X X X
15 Pons X X X
16 Medulla X X X X
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CONNECT-TBI network sites, into a centralized data-
base that is shared with participating CONNECT-TBI 
centers and eventually with the wider research commu-
nity. The Data Coordinating Core will also provide epi-
demiological and statistical support in analyses of data 
generated through associated Research Projects.
In collaboration with NINDS, key external investigators 
and the FITBIR program, the Data Coordinating Core 
will develop common data elements (CDEs) and unique 
data elements (UDEs) specific to TReND. These CDEs 
and UDEs will form the basis for all digital neuropatho-
logical data and clinical data that will be collected in all 
CONNNECT-TBI center projects. CDEs will be classified 
as being either a “core” CDE (a data element that collects 
essential information applicable to any study, including 
either those which span across all disease and therapeu-
tic areas or those that are specific to one disease area), 
a “supplemental highly-recommended” CDE (a data ele-
ment that is essential based on certain conditions or 
study types in clinical research studies), a “supplemental” 
CDE (a data element that is commonly collected in clini-
cal research studies but whose relevance depends upon 
the study design (i.e., clinical trial, cohort study, etc.) or 
type of research involved), or an “exploratory” CDE (a 
data element that requires further validation), but may fill 
current gaps in the CDEs and/or substitute for an exist-
ing CDE once validation is complete.
All clinical history data for retrospective/archive 
cases were collected via a self- or proxy-report assess-
ment. However, for prospective cases, participating 
centers will be collecting information using the Brain 
Injury Screening Questionnaire (BISQ) [3]; a struc-
tured and well-validated assessment which will provide 
a degree of standardization for the acquisition of clinical 
information.
The Data Coordinating Core will collate and store all 
data associated with the program and will provide ana-
lytical assistance in analyzing specific data. For example, 
the results from the neuropathology assessments of the 
Expert Consensus Group will be collated and outputs 
generated on distinction and overlap between TReND 
and the pathologies of wider neurodegenerative diseases 
and aging.
CONNECT‑TBI portal
An overarching goal of the CONNECT-TBI program 
is the creation of a fully characterized research tissue 
resource linked to comprehensive clinical datasets to 
support wider, investigator-initiated enquiries in TBI. 
The CONNECT-TBI website facilitates  access to this 
archive and associated pathology and clinical datasets. 
Requests for data or digital scans will be made through 
formal online applications to be approved by the CON-
NECT-TBI Administrative Core. Tissue requests will 
be directed to one of the participating CONNECT-TBI 
brain banks for tissue and data transfer. The CONNECT-
TBI website will also host information on the overarching 
program aims, the investigator team and host institu-
tions, communicate CONNECT-TBI program outputs, 
act as a central repository for all CONNECT-TBI pro-
gram-generated ‘best practice’ protocols and procedures 
for archiving and assessing materials from individuals 
exposed to TBI, and will be the access point for tissue 
and image sharing (Fig. 3).
Results
CONNECT‑TBI existing archive holdings
The current holdings across the CONNECT-TBI pro-
gram comprise research tissue samples from almost 2000 
acute TBI (aTBI) and over 900 chronic TBI (cTBI) cases. 
Regarding cTBI cases, these comprise 559 civilian, 143 
sport (e.g.  football, soccer, hockey, rugby, boxing) and 
268 former military personnel (Table 2).
From each CONNECT-TBI center, standardized CDEs 
and UDEs on each case are being collated to the central 
CONNECT-TBI archive dataset to include, where avail-
able: patient demographics (including age, sex, ethnicity); 
TBI injury details including mechanism, severity, medi-
cal interventions and survival interval; clinical recov-
ery (including estimates of extended Glasgow Outcome 
Scale, cognitive function, post-traumatic epilepsy); doc-
umented known medical comorbidities; tissue samples 
archived (including anatomical locations, whether fixed 
or frozen tissue available); and results of neuropathologi-
cal assessments (including assessments of neurodegener-
ative disease pathologies). Review of the CONNECT-TBI 
centers with research tissue banks in neurodegeneration, 
identifies tissue samples from over 2000 donors with AD, 
over 850 donors with Parkinson’s/Lewy body disease and 
over 3500 with other neurodegenerative diseases, such as 
frontotemporal lobar degeneration, in addition to mate-
rial from normal controls with no known history of TBI 
or neurodegenerative disease (Table 3).
CONNECT‑TBI new case consensus review and archiving
All CONNECT-TBI centers contribute material from 
new research brain donations for Expert Consensus 
Group diagnostic review and archiving. In year 1 of 
CONNECT-TBI, a total of 141 cases have been accrued 
across centers: 36 from individuals with a history of TBI 
and/or exposure to repetitive head impacts, the remain-
der as non-TBI associated neurodegenerative disease 
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(n = 100) or controls with no history of TBI or neurode-
generative disease (n = 5). Demographic information and 
neuropathological diagnoses for these cases are shown in 
Table 4. 
Fig. 3 Process for research tissue sharing. (1) Researcher contacts Administrative Core in project planning phase to establish whether suitable 
resources within CONNECT‑TBI networked archive are available to support their proposal. (2) Application submitted to Scientific Review Board for 
approval. (3) Following project approval by Scientific Review Board, CONNECT‑TBI provides specific case numbers and institution contact details to 
researcher thereby initiating transfer
Table 2 Current tissue holdings of acute and chronic TBI across CONNECT-TBI centers
aTBI acute survival from traumatic brain injury, cTBI chronic survival from traumatic brain injury, USUHS Uniformed Services University of the Health Sciences
Civilian Sport Military Total
aTBI cTBI aTBI cTBI aTBI cTBI aTBI cTBI
University of Glasgow 1654 139 5 25 0 1 1659 165
University of Pennsylvania 3 90 0 26 0 18 3 134
Massachusetts General 16 2 0 0 0 0 16 2
Mount Sinai 0 22 0 8 0 6 0 36
New York University 295 77 0 0 0 7 295 84
University of Pittsburgh 3 55 0 13 0 1 3 69
University of Toronto 0 6 2 50 0 0 2 56
University of Washington 8 159 0 19 0 46 8 224
USUHS 7 9 0 2 5 189 12 200
Total 1986 559 7 143 5 268 1998 970
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Index case
Clinical history
A subject who died in his 70s first reported notable 
symptoms in his early 60s. At that time, he noticed mild 
incoordination, with associated impaired visuospatial 
awareness, leading to his frequently bumping into sta-
tionary objects. He had also developed a shuffling gait, 
with occasional instances where he would catch his foot 
on a floor surface and trip, without falling. In the fol-
lowing years he reported increasingly vivid, distressing 
dreams and visual hallucinations, which he eventually 
lost insight to. These evolving symptoms were associ-
ated with mood change, which his family described as a 
somewhat flat affect. Approximately 6 years after symp-
tom onset, he developed difficulties with speech, with 
limiting of vocabulary and hesitancy on production. He 
was initially  examined by a primary care physician who 
noted no apparent deficit in routine clinical or memory 
screening tests, but nevertheless arranged for review by 
secondary care mental health services. At this review, 
formal cognitive assessment with Addenbrooke’s Cogni-
tive Examination (ACE) noted a score of 81/100, and an 
initial diagnosis of mild cognitive impairment (amnes-
tic type) was suggested; later revised to Alzheimer’s 
dementia when functional abilities were lost. Treatment 
with psychosocial interventions and acetylcholinester-
ase inhibitor medication was commenced. In the years 
that followed, there was a steady decline in his condition 
requiring increasing assistance with self-care, such that 
3 years after this initial review and diagnosis he was tran-
sitioned to residential care for ongoing support, where he 
remained until his death.
The subject had a history of mild anxiety and depressive 
symptoms noted from his 50s, which was managed by his 
primary physician and did not require psychotropic med-
ication or inpatient services. There was no documented 
history of suicidal ideation. Other than prior knee surger-
ies, the patient is described as having been in excellent 
health and had no history of alcohol or recreational drug 
dependency. There is no notable family history of neuro-
degenerative disease or of mental disorder.
The patient was a former soccer player (amateur and 
professional), playing as a defender and retiring in his 
mid-30s. During his sporting career, he is known to have 
sustained at least two mild traumatic brain injuries with 
documented brief loss of consciousness with nonspecific 
symptomology in the following 2-week period. No other 
history of TBI was noted. The patient did not participate 
in combat sports and had no history of military service.
Table 3 Current tissue holdings in  neurodegenerative 





University of Pennsylvania 627 386 758 1771
University of Pittsburgh 808 81 794 1683
University of Washington 858 407 2096 3361
Total CONNECT‑TBI NDD 2293 874 3645 6815
Table 4 Demographic information and neuropathological diagnoses for Year 1 CONNECT-TBI new case donations
ADNC Alzheimer’s disease neuropathologic changes, ARTAG aging-related tau astrogliopathy, CTE-NC chronic traumatic encephalopathy neuropathologic change, 
CVD cerebrovascular disease, FTLD frontotemporal lobar degeneration, LBD Lewy body disease, NA not applicable, TBI traumatic brain injury
History of TBI No history of TBI
Number of cases 36 (26%) 105 (74%)
Male 27 (75%) 58 (55%)
Mean age (range) 65 (20–93) 75 (31–100)
n (%) n (%)
TBI exposure
Sport 14 (39) NA
Military 3 (8) NA
Civilian 33 (92) NA
Multiple 7 (19) NA
Neuropathology
CTE‑NC 8 (22) 0 (0)
ADNC 20 (56) 71 (68)
LBD 8 (22) 42 (40)
ARTAG 12 (33) 48 (46)
FTLD 2 (6) 9 (9)
CVD 3 (8) 32 (31)
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Post‑mortem findings
At autopsy, the intact, formalin-fixed brain weighed 
1400 g, with the hindbrain weight 195 g. The cerebral 
hemispheres were symmetrical with a normal lobula-
tion and gyral architecture. Mild atrophy of the gyri over 
the frontal and temporal poles was noted, associated 
with widening of the sulci and gelatinous thickening of 
the overlying meninges. Otherwise the external appear-
ances were unremarkable. On sectioning the cerebral 
hemispheres in the coronal plane, there was noted fen-
estration of the septum pellucidum, particularly towards 
the posterior extent where it was virtually absent (Fig. 4). 
Elsewhere there was cortical atrophy with thinning of 
the frontal and temporal gyri, bilateral hippocampal 
atrophy and ventriculomegaly. The cerebellum appeared 
unremarkable externally and on sectioning, with no 
notable abnormalities in the brainstem; the substantia 
nigra pigmentation appearing within normal limits for 
the patient’s age. There was no macroscopic evidence of 
recent or previous TBI.
Systemic examination revealed macroscopic evidence 
of abundant yellow fluid emerging from the cut surfaces 
Fig. 4 Representative images of pathology of illustrative case. Fenestration of the septum pellucidum (a). Cortical pTau in neurons and glia 
consistent with neurofibrillary tangles of Alzheimer’s disease neuropathologic change and astrocytic pathology of aging‑related tau astrogliopathy 
(b, e; PHF‑1), with abundant neurofibrillary tangles also present in hippocampal sector CA1 (d; PHF‑1). In addition, frequent neuritic amyloid plaques 
and cerebral amyloid (arrowhead) were present (c; 6f3d). Elsewhere, numerous cytoplasmic inclusions immunoreactive for phospho‑TDP‑43 
were identified in the dentate granule cell layer (f; 1D3). Within the substantia nigra numerous classical Lewy bodies were present (G; arrow), with 
frequent cortical Lewy bodies revealed in staining for alpha‑synuclein (h; KM51)
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of the airways of the lower and posterior segments of the 
lungs bilaterally. Histological sections of the lungs con-
firmed features of an established bronchopneumonia in 
association with scattered clusters of rounded bacterial 
organisms. Otherwise, the systemic examination was 
essentially unremarkable.
Neuropathology expert consensus evaluation
Multiple brain tissue samples were processed consistent 
with the CONNECT-TBI new case evaluation protocol, 
with the resultant stained sections then scanned and dis-
tributed to the Expert Consensus Group for review and 
assessment of TReND pathologies (Fig.  4). Ten of 13 
members of the Expert Consensus Group provided inde-
pendent evaluations of the pathologies in this case, with 
consensus achieved for multiple evaluations at this first 
review (Table 5).
The remaining pathologies for which no immediate 
consensus was achieved were discussed during a vide-
oconference call between the Expert Consensus Group 
with access to the scanned slides (13/16 ECG members 
were present). This resulted in consensus being achieved 
for all pathologies under evaluation, with a final inte-
grated diagnosis of neurodegenerative disease recorded 
as dementia with Lewy bodies, with noted comorbid 
pathologies as: intermediate ADNC; TDP-43 proteinopa-
thy; ARTAG; CAA; and low CVD pathology (Fig. 4).
Discussion
CONNECT-TBI has established a network of interna-
tionally recognized brain banks and academic institu-
tions creating a comprehensive tissue and data resource 
in human TBI to support studies by the wider research 
community. Among the available resources is case mate-
rial from patients across all injury  survival intervals, 
and  from across the broad spectrum of injury subtypes, 
including civilian, military and sports. Leveraging these 
resources, CONNECT-TBI has begun to characterize the 
extent, distribution and range of neuropathologies that 
result following exposure to TBI, specifically the patholo-
gies associated with TReND.
The CONNECT-TBI network will unify characterized 
tissue resources and comprehensive clinical data sets 
which will advance research into the neuropathologi-
cal features of TReND, healthy ageing, and neurodegen-
erative diseases more widely. However, it is recognized 
that an unavoidable limitation of the network design is 
a reliance on self- or proxy-report assessment in clini-
cal histories, which may be incomplete for archive cases. 
Investigating associations of neuropathological and 
clinical outcomes following TBI with a range of patient 
variables might therefore be challenging. However, for 
prospective cases, participating centers will be asked 
to collect information using the Brain Injury Screening 
Questionnaire (BISQ); a structured and well-validated 
assessment which will provide a degree of standardiza-
tion for the acquisition of clinical information.
With the increasingly global nature of research, sus-
taining major international collaborations can present 
challenges, particularly those that require detailed exami-
nation of human tissue. CONNECT-TBI has shown that 
a centralized archive of digitally scanned stained tissue 
sections can be distributed, examined and assessed effi-
ciently using established neuropathological criteria and 
in a timely manner. Supplemented with virtual group 
discussions that include live slide examinations, there 
is opportunity for continued case review and consensus 
diagnostic evaluation of the spectrum of TReND.
Although animal models can provide valuable infor-
mation, particularly with respect to examining specified 
time points and investigating potential mechanisms of 
injury, there are considerable recognized limitations of 
pre-clinical studies in informing on human TBI. To date, 
in excess of 30 clinical trials of candidate therapies for 
TBI have failed, despite early promise from pre-clinical 
studies. The multidisciplinary expertise contributing to 
the CONNECT-TBI program provides opportunity for 
rigorous, unbiased evaluation of both clinical and neuro-
pathological facets of TReND that can be used to inform 
mechanistic studies and therapeutic strategies. Current 
consensus criteria for the neuropathological assessment 
of CTE are based on a limited number of cases. The 
number of cases required to characterize TReND com-
prehensively exceeds the capability of individual biore-
positories. Availability of human tissues for research 
purposes is often impeded by the demands on expertise 
and resources required to establish suitable tissue bank-
ing facilities. CONNECT-TBI aims to fill this void by 
providing a central point of access to multiple centers for 
both physical and virtual tissue.
Conclusions
A central brain tissue repository with access to clini-
cal data in large archives of fully characterized TBI and 
neurodegenerative disease cases, with appropriate age-
matched non-injured controls and associated clini-
cal data, will be a priceless resource to the greater TBI 
research community. This resource will be utilized to 
generate a consensus in the operational criteria for the 
diagnosis of TReND across all range and subtypes and to 
evaluate the extent and distribution of all neuropatholo-
gies resulting from TBI exposure. Furthermore, the 
center will seek to contrast the phenotypes of TReND 
with that of wider neurodegenerative disease and with 
aging processes. In all, the CONNECT-TBI collaboration 
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will represent a broad, comprehensive exploration of the 
intricate neuropathological changes following TBI.
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